Literature DB >> 30004704

Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.

Clarissa G Jakob, Anup K Upadhyay, Pamela L Donner, Emily Nicholl, Sadiya N Addo, Wei Qiu, Christopher Ling, Sujatha M Gopalakrishnan, Maricel Torrent, Steven P Cepa, Jason Shanley, Alexander R Shoemaker, Chaohong C Sun, Anil Vasudevan, Kevin R Woller, J Brad Shotwell, Bailin Shaw, Zhiguo Bian, Jessica E Hutti.   

Abstract

IDH1 plays a critical role in a number of metabolic processes and serves as a key source of cytosolic NADPH under conditions of cellular stress. However, few inhibitors of wild-type IDH1 have been reported. Here we present the discovery and biochemical characterization of two novel inhibitors of wild-type IDH1. In addition, we present the first ligand-bound crystallographic characterization of these novel small molecule IDH1 binding pockets. Importantly, the NADPH competitive α,β-unsaturated enone 1 makes a unique covalent linkage through active site H315. As few small molecules have been shown to covalently react with histidine residues, these data support the potential utility of an underutilized strategy for reversible covalent small molecule design.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30004704     DOI: 10.1021/acs.jmedchem.8b00305

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.

Authors:  Tinghu Zhang; John M Hatcher; Mingxing Teng; Nathanael S Gray; Milka Kostic
Journal:  Cell Chem Biol       Date:  2019-10-17       Impact factor: 8.116

2.  Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.

Authors:  Chan Chung; Stefan R Sweha; Drew Pratt; Benita Tamrazi; Pooja Panwalkar; Adam Banda; Jill Bayliss; Debra Hawes; Fusheng Yang; Ho-Joon Lee; Mengrou Shan; Marcin Cieslik; Tingting Qin; Christian K Werner; Daniel R Wahl; Costas A Lyssiotis; Zhiguo Bian; J Brad Shotwell; Viveka Nand Yadav; Carl Koschmann; Arul M Chinnaiyan; Stefan Blüml; Alexander R Judkins; Sriram Venneti
Journal:  Cancer Cell       Date:  2020-08-13       Impact factor: 31.743

3.  Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.

Authors:  Jennifer M Chambers; Wade Miller; Giovanni Quichocho; Viraj Upadhye; Diego Avellaneda Matteo; Andrey A Bobkov; Christal D Sohl; Jamie M Schiffer
Journal:  Biochemistry       Date:  2020-01-13       Impact factor: 3.162

Review 4.  An overview of ghrelin O-acyltransferase inhibitors: a literature and patent review for 2010-2019.

Authors:  Jacob E Moose; Katelyn A Leets; Nilamber A Mate; John D Chisholm; James L Hougland
Journal:  Expert Opin Ther Pat       Date:  2020-06-21       Impact factor: 6.674

5.  Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72.

Authors:  Jonathan Pettinger; Michael Carter; Keith Jones; Matthew D Cheeseman
Journal:  J Med Chem       Date:  2019-12-06       Impact factor: 7.446

6.  Design and Synthesis of New 6-Nitro and 6-Amino-3,3a,4,5-Tetrahydro-2H-Benzo[g]indazole Derivatives: Antiproliferative and Antibacterial Activity.

Authors:  Viviana Cuartas; María Del Pilar Crespo; Eva-María Priego; Leentje Persoons; Dirk Daelemans; María-José Camarasa; Braulio Insuasty; María-Jesús Pérez-Pérez
Journal:  Molecules       Date:  2019-11-21       Impact factor: 4.411

7.  Palladium-Catalyzed α-Arylation of Cyclic β-Dicarbonyl Compounds for the Synthesis of CaV1.3 Inhibitors.

Authors:  Jisu Yun; Dayeon Jeong; Zhong Xie; Sol Lee; Jiho Kim; D James Surmeier; Richard B Silverman; Soosung Kang
Journal:  ACS Omega       Date:  2022-04-12

8.  Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.

Authors:  Mehrdad Zarei; Omid Hajihassani; Jonathan J Hue; Hallie J Graor; Alexander W Loftus; Moeez Rathore; Ali Vaziri-Gohar; John M Asara; Jordan M Winter; Luke D Rothermel
Journal:  J Exp Clin Cancer Res       Date:  2022-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.